Benefit of Bone Drug in Prostate Cancer in Doubt - MedPage Today

Benefit of Bone Drug in Prostate Cancer in Doubt MedPage Today In documents released Monday, FDA reviewers assessed Amgen's study of 1432 men with nonmetastatic, castration-resistant prostate cancer who were randomized to calcium and vitamin D supplements plus either 120 mg subcutaneous denosumab every four weeks ... and more »

Bone Drug Slows Mets in Aggressive Prostate Ca - MedPage Today

Bone Drug Slows Mets in Aggressive Prostate Ca MedPage Today SAN FRANCISCO -- Denosumab (Xgeva) delays the onset of bone metastases for even the highest risk prostate cancer patients, researchers found. The relative benefit of denosumab on survival time compared with placebo was greatest in patients at highest ... and more »